Inventor
YARRANTON GEOFFREY T
US26 patents
⚠️ This page may combine multiple inventors who share the name “YARRANTON GEOFFREY T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MEDAREX INC
8 patentsUS7129261B2Oct 31, 2006
Cytotoxic agents
MEDAREX INC282 citations98
US7214663B2May 8, 2007
Tripeptide prodrug compounds
MEDAREX INC52 citations96
US7115573B2Oct 3, 2006
Prodrug compounds with an isoleucine
MEDAREX INC61 citations96
US7329507B2Feb 12, 2008
Prodrug compounds with isoleucine
MEDAREX INC27 citations92
US7939076B2May 10, 2011
Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
MEDAREX INC9 citations84
US7816317B2Oct 19, 2010
Tripeptide prodrug compounds
MEDAREX INC13 citations84
US8034787B2Oct 11, 2011
Enzyme-cleavable prodrug compounds
MEDAREX INC8 citations82
US7696313B2Apr 13, 2010
Prodrug compounds with isoleucine
MEDAREX INC7 citations73
BEBBINGTON CHRISTOPHER R
5 patentsUS8398972B2Mar 19, 2013
Methods of treating dementia using a GM-CSF antagonist
BEBBINGTON CHRISTOPHER R9 citations81
US8075885B2Dec 13, 2011
Methods of treating heart failure using an anti-GM-CSF antibody
BEBBINGTON CHRISTOPHER R6 citations73
US8168183B2May 1, 2012
Antibodies to granulocyte-macrophage colony-stimulating factor
BEBBINGTON CHRISTOPHER R4 citations61
US8877191B2Nov 4, 2014
Antibodies to the PcrV antigen of Pseudomonas aeruginosa
BEBBINGTON CHRISTOPHER R0 citations50
US8834870B2Sep 16, 2014
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
BEBBINGTON CHRISTOPHER R0 citations49
YARRANTON GEOFFREY T
4 patentsUS8642039B2Feb 4, 2014
Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
YARRANTON GEOFFREY T4 citations71
US8211648B2Jul 3, 2012
Secretion of antibodies without signal peptides from bacteria
YARRANTON GEOFFREY T2 citations61
US9127046B2Sep 8, 2015
Secretion of antibodies without signal peptides from bacteria
YARRANTON GEOFFREY T0 citations51
US9109032B2Aug 18, 2015
Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
YARRANTON GEOFFREY T1 citations48
KALOBIOS PHARMACEUTICALS INC
3 patentsUS7981843B2Jul 19, 2011
Antibody specificity transfer using minimal essential binding determinants
KALOBIOS PHARMACEUTICALS INC36 citations90
US9290571B2Mar 22, 2016
Antibodies to EphA3
KALOBIOS PHARMACEUTICALS INC0 citations50
US8044181B2Oct 25, 2011
Antibodies to the PcrV antigen of Pseudomonas aeruginosa
KALOBIOS PHARMACEUTICALS INC0 citations50